Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | yes | yes: 9 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005847 | mRNA cleavage and polyadenylation specificity factor complex | 4 | 1 |
GO:0005849 | mRNA cleavage factor complex | 3 | 1 |
GO:0032991 | protein-containing complex | 1 | 1 |
GO:0140513 | nuclear protein-containing complex | 2 | 1 |
Related structures:
AlphaFold database: A0A3Q8IAT5
Term | Name | Level | Count |
---|---|---|---|
GO:0006139 | nucleobase-containing compound metabolic process | 3 | 12 |
GO:0006379 | mRNA cleavage | 7 | 12 |
GO:0006725 | cellular aromatic compound metabolic process | 3 | 12 |
GO:0006807 | nitrogen compound metabolic process | 2 | 12 |
GO:0008152 | metabolic process | 1 | 12 |
GO:0009987 | cellular process | 1 | 12 |
GO:0016070 | RNA metabolic process | 5 | 12 |
GO:0016071 | mRNA metabolic process | 6 | 12 |
GO:0034641 | cellular nitrogen compound metabolic process | 3 | 12 |
GO:0043170 | macromolecule metabolic process | 3 | 12 |
GO:0044237 | cellular metabolic process | 2 | 12 |
GO:0044238 | primary metabolic process | 2 | 12 |
GO:0046483 | heterocycle metabolic process | 3 | 12 |
GO:0071704 | organic substance metabolic process | 2 | 12 |
GO:0090304 | nucleic acid metabolic process | 4 | 12 |
GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 5 | 12 |
GO:0090501 | RNA phosphodiester bond hydrolysis | 6 | 12 |
GO:0098787 | mRNA cleavage involved in mRNA processing | 8 | 12 |
GO:0098789 | pre-mRNA cleavage required for polyadenylation | 9 | 12 |
GO:1901360 | organic cyclic compound metabolic process | 3 | 12 |
GO:0006396 | RNA processing | 6 | 1 |
GO:0006397 | mRNA processing | 7 | 1 |
GO:0031426 | polycistronic mRNA processing | 8 | 1 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003676 | nucleic acid binding | 3 | 12 |
GO:0003723 | RNA binding | 4 | 12 |
GO:0005488 | binding | 1 | 12 |
GO:0008270 | zinc ion binding | 6 | 12 |
GO:0043167 | ion binding | 2 | 12 |
GO:0043169 | cation binding | 3 | 12 |
GO:0046872 | metal ion binding | 4 | 12 |
GO:0046914 | transition metal ion binding | 5 | 12 |
GO:0097159 | organic cyclic compound binding | 2 | 12 |
GO:1901363 | heterocyclic compound binding | 2 | 12 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 122 | 124 | PF00675 | 0.358 |
CLV_NRD_NRD_1 | 250 | 252 | PF00675 | 0.263 |
CLV_NRD_NRD_1 | 298 | 300 | PF00675 | 0.599 |
CLV_NRD_NRD_1 | 301 | 303 | PF00675 | 0.594 |
CLV_NRD_NRD_1 | 333 | 335 | PF00675 | 0.695 |
CLV_PCSK_FUR_1 | 299 | 303 | PF00082 | 0.709 |
CLV_PCSK_KEX2_1 | 122 | 124 | PF00082 | 0.365 |
CLV_PCSK_KEX2_1 | 138 | 140 | PF00082 | 0.392 |
CLV_PCSK_KEX2_1 | 174 | 176 | PF00082 | 0.532 |
CLV_PCSK_KEX2_1 | 250 | 252 | PF00082 | 0.387 |
CLV_PCSK_KEX2_1 | 297 | 299 | PF00082 | 0.596 |
CLV_PCSK_KEX2_1 | 301 | 303 | PF00082 | 0.591 |
CLV_PCSK_KEX2_1 | 332 | 334 | PF00082 | 0.701 |
CLV_PCSK_PC1ET2_1 | 138 | 140 | PF00082 | 0.517 |
CLV_PCSK_PC1ET2_1 | 174 | 176 | PF00082 | 0.524 |
CLV_PCSK_PC7_1 | 297 | 303 | PF00082 | 0.711 |
CLV_PCSK_SKI1_1 | 135 | 139 | PF00082 | 0.363 |
CLV_PCSK_SKI1_1 | 174 | 178 | PF00082 | 0.512 |
CLV_PCSK_SKI1_1 | 192 | 196 | PF00082 | 0.373 |
CLV_PCSK_SKI1_1 | 251 | 255 | PF00082 | 0.384 |
DEG_Nend_Nbox_1 | 1 | 3 | PF02207 | 0.467 |
DOC_MAPK_gen_1 | 174 | 182 | PF00069 | 0.386 |
DOC_USP7_MATH_1 | 111 | 115 | PF00917 | 0.468 |
DOC_USP7_MATH_1 | 214 | 218 | PF00917 | 0.520 |
DOC_USP7_MATH_1 | 285 | 289 | PF00917 | 0.710 |
LIG_14-3-3_CanoR_1 | 48 | 57 | PF00244 | 0.478 |
LIG_Actin_WH2_2 | 54 | 69 | PF00022 | 0.331 |
LIG_BIR_III_2 | 43 | 47 | PF00653 | 0.506 |
LIG_BIR_III_4 | 5 | 9 | PF00653 | 0.546 |
LIG_FHA_1 | 231 | 237 | PF00498 | 0.692 |
LIG_FHA_2 | 259 | 265 | PF00498 | 0.367 |
LIG_FHA_2 | 7 | 13 | PF00498 | 0.541 |
LIG_FHA_2 | 98 | 104 | PF00498 | 0.415 |
LIG_LIR_Nem_3 | 52 | 57 | PF02991 | 0.503 |
LIG_PCNA_PIPBox_1 | 58 | 67 | PF02747 | 0.335 |
LIG_REV1ctd_RIR_1 | 90 | 99 | PF16727 | 0.506 |
LIG_SH2_CRK | 54 | 58 | PF00017 | 0.497 |
LIG_SH2_GRB2like | 82 | 85 | PF00017 | 0.480 |
LIG_SH2_STAP1 | 167 | 171 | PF00017 | 0.447 |
LIG_SH2_STAP1 | 82 | 86 | PF00017 | 0.331 |
LIG_SH2_STAT3 | 86 | 89 | PF00017 | 0.450 |
LIG_SH2_STAT5 | 146 | 149 | PF00017 | 0.429 |
LIG_SH2_STAT5 | 78 | 81 | PF00017 | 0.241 |
LIG_SH2_STAT5 | 86 | 89 | PF00017 | 0.306 |
LIG_SH3_3 | 124 | 130 | PF00018 | 0.345 |
LIG_SH3_3 | 149 | 155 | PF00018 | 0.438 |
LIG_SH3_3 | 206 | 212 | PF00018 | 0.387 |
LIG_SH3_3 | 226 | 232 | PF00018 | 0.293 |
LIG_SH3_3 | 279 | 285 | PF00018 | 0.765 |
LIG_SH3_3 | 99 | 105 | PF00018 | 0.404 |
LIG_TRAF2_1 | 162 | 165 | PF00917 | 0.438 |
MOD_CK2_1 | 111 | 117 | PF00069 | 0.370 |
MOD_CK2_1 | 97 | 103 | PF00069 | 0.404 |
MOD_Cter_Amidation | 330 | 333 | PF01082 | 0.635 |
MOD_GlcNHglycan | 140 | 143 | PF01048 | 0.558 |
MOD_GlcNHglycan | 192 | 195 | PF01048 | 0.431 |
MOD_GlcNHglycan | 237 | 240 | PF01048 | 0.718 |
MOD_GlcNHglycan | 287 | 290 | PF01048 | 0.722 |
MOD_GlcNHglycan | 312 | 315 | PF01048 | 0.739 |
MOD_GlcNHglycan | 51 | 54 | PF01048 | 0.444 |
MOD_GSK3_1 | 186 | 193 | PF00069 | 0.523 |
MOD_GSK3_1 | 49 | 56 | PF00069 | 0.369 |
MOD_LATS_1 | 136 | 142 | PF00433 | 0.492 |
MOD_N-GLC_1 | 111 | 116 | PF02516 | 0.457 |
MOD_N-GLC_1 | 190 | 195 | PF02516 | 0.373 |
MOD_NEK2_1 | 106 | 111 | PF00069 | 0.594 |
MOD_NEK2_1 | 13 | 18 | PF00069 | 0.463 |
MOD_NEK2_1 | 190 | 195 | PF00069 | 0.495 |
MOD_PIKK_1 | 111 | 117 | PF00454 | 0.446 |
MOD_PKA_1 | 138 | 144 | PF00069 | 0.489 |
MOD_PKA_2 | 138 | 144 | PF00069 | 0.441 |
MOD_Plk_1 | 13 | 19 | PF00069 | 0.511 |
MOD_Plk_2-3 | 258 | 264 | PF00069 | 0.384 |
MOD_Plk_4 | 214 | 220 | PF00069 | 0.516 |
MOD_SUMO_for_1 | 137 | 140 | PF00179 | 0.494 |
MOD_SUMO_rev_2 | 20 | 28 | PF00179 | 0.582 |
TRG_ENDOCYTIC_2 | 54 | 57 | PF00928 | 0.502 |
TRG_ER_diArg_1 | 121 | 123 | PF00400 | 0.345 |
TRG_ER_diArg_1 | 297 | 299 | PF00400 | 0.690 |
TRG_ER_diArg_1 | 300 | 302 | PF00400 | 0.693 |
TRG_ER_diArg_1 | 332 | 334 | PF00400 | 0.701 |
TRG_ER_diArg_1 | 38 | 41 | PF00400 | 0.506 |
TRG_Pf-PMV_PEXEL_1 | 221 | 225 | PF00026 | 0.552 |
TRG_Pf-PMV_PEXEL_1 | 298 | 303 | PF00026 | 0.644 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1PEE4 | Leptomonas seymouri | 87% | 100% |
A0A0S4KP33 | Bodo saltans | 50% | 99% |
A0A1X0NMX4 | Trypanosomatidae | 59% | 100% |
A0A3R7KCZ6 | Trypanosoma rangeli | 60% | 100% |
A4H5Q3 | Leishmania braziliensis | 97% | 100% |
A4HTZ3 | Leishmania infantum | 100% | 100% |
D0A9F4 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 58% | 100% |
E9AMS3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 98% | 100% |
O95639 | Homo sapiens | 33% | 100% |
Q4QHV2 | Leishmania major | 98% | 100% |
V5D8L4 | Trypanosoma cruzi | 65% | 100% |